Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 87

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 87
---
 is calculated as the amount by which that closing market price exceeds the exercise price for unvested stock options at December 31, 2024. The value of the acceleration of vesting of awards is calculated as the amount of unvested and unearned awards multiplied by the closing market price on December 31, 2024 and assumes that any performance conditions for PSUs are satisfied in full. |

| (2) | Represents the cost of premiums for medical, dental, vision, life and disability insurance coverage under our group employee benefit plans based on 2024 rates. |

| (3) | As described under “Potential Payments Upon Termination of Change in Control”, the total payment following a change in control will be reduced to a level below the Section 280G safe harbor amount. Under the assumptions above, Mr. Pletcher exceeded the 280G safe harbor amount as of December 31, 2024 and as a result his payment would have be reduced below the safe harbor amount. Mr. Pletcher, however, resigned his employment in March 2025. Mr. Pletcher was not entitled to receive any termination benefits in connection with his resignation. |

| (4) | Mr. Jaw resigned his employment effective February 23, 2024. In connection with Mr. Jaw’s resignation, we entered into a consulting agreement with him as described under “Compensation Discussion and Analysis—Compensation Components—Severance Benefits and Employment Agreements.” |

Principal Executive Officer Pay Ratio Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act and the related SEC rule (the “Rule”), the following table provides the ratio of the total compensation for 2024 for Mr. Blum, our principal executive officer to the total compensation for 2024 for our median employee follows:

| PEO Compensation for 2024                                          |     | $14,368,343 |
| Median Employee Compensation for 2024                              |     |    $411,825 |
| Ratio of PEO Compensation to Median Employee Compensation for 2024 |     |     35 to 1 |

| 60 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS EXECUTIVE COMPENSATION The pay ratio above represents the Company’s reasonable estimate calculated in a manner consistent with the Rule and applicable guidance. The Rule and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company.